At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 217 enrolled
Drug / intervention
Zanubrutinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined With Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/ Refractory Follicular Lymphoma
In Brief
A Phase 2 clinical trial evaluating Zanubrutinib and Obinutuzumab for Relapsed/Refractory Follicular Non-Hodgkin Lymphoma. Completed, enrolled 217 participants across 88 sites in 17 countries.
Detailed Summary
This clinical study examined the safety and efficacy of the combination of zanubrutinib and obinutuzumab versus obinutuzumab alone in adults with follicular lymphoma whose disease returned after or did not respond to prior therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustralia, Belarus, Bulgaria, Canada, China, Czechia, France, Germany, Italy, New Zealand, Poland, Russia, South Korea, Spain, Taiwan, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedNov 2017
Enrollment StartNov 2017
Primary CompletionOct 2021
Study CompletionDec 2024
TodayJul 2026
First PostedNov 6, 2017
Enrollment StartNov 14, 2017
Primary CompletionOct 8, 2021
Study CompletionDec 27, 2024
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 8.7 years ago
Interventions
Zanubrutinibdrug
Oral administration as a capsule
Obinutuzumabdrug
Intravenous administration